Which phase is primarily concerned with establishing safety and efficacy in a broad patient population and is often the pivotal trial for regulatory approval?

Which phase is primarily concerned with establishing safety and efficacy in a broad patient population and is often the pivotal trial for regulatory approval?

• A. Phase 1
• B. Phase 2
• C. Phase 3
• D. Phase 4

Answer: (C)

Phase 3 trials are the stage where the therapy is tested in a broad and diverse group of patients to confirm it provides meaningful benefit with an acceptable safety profile. These trials are large, randomized, and controlled, often multicenter, sometimes multinational, with endpoints that reflect real clinical use. They are designed to show that benefits seen earlier apply across patient subgroups and to define the dose and treatment regimens that will be recommended on labeling. Because the evidence from Phase 3 is typically the primary basis for regulatory approval, it is described as pivotal. In contrast, Phase 1 focuses on safety and pharmacology in a small group, Phase 2 looks for preliminary efficacy and optimal dose in more patients, and Phase 4 monitors safety after approval in the general population.

Phase 3 trials are the stage where the therapy is tested in a broad and diverse group of patients to confirm it provides meaningful benefit with an acceptable safety profile. These trials are large, randomized, and controlled, often multicenter, sometimes multinational, with endpoints that reflect real clinical use. They are designed to show that benefits seen earlier apply across patient subgroups and to define the dose and treatment regimens that will be recommended on labeling. Because the evidence from Phase 3 is typically the primary basis for regulatory approval, it is described as pivotal. In contrast, Phase 1 focuses on safety and pharmacology in a small group, Phase 2 looks for preliminary efficacy and optimal dose in more patients, and Phase 4 monitors safety after approval in the general population.